Matching articles for "Afrezza"
Issue 1743 · December 8, 2025
Insulins for Type 2 Diabetes

The goal of pharmacologic treatment for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration while minimizing hypoglycemia; an A1C goal of <7% is recommended for…

Med Lett Drugs Ther. 2025 Dec 8; 67(1743):196-9 doi:10.58347/tml.2025.1743c
The goal of pharmacologic treatment for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration while minimizing hypoglycemia; an A1C goal of <7% is recommended for most patients to prevent or reduce the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy). An A1C target of <8% may be appropriate for patients who are older, have comorbid conditions, or are at risk for serious hypoglycemia-associated adverse events.
Issue 1743 · December 8, 2025 Free
Comparison Chart: Some Available Insulins for Type 2 Diabetes (online only)

View the Comparison Chart: Some Available Insulins for Type 2 Diabetes

Med Lett Drugs Ther. 2025 Dec 8; 67(1743):e201-4 doi:10.58347/tml.2025.1743d
View the Comparison Chart: Some Available Insulins for Type 2 Diabetes
Issue 1571 · May 6, 2019
Insulins for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is <7%. Metformin…

Med Lett Drugs Ther. 2019 May 6; 61(1571):65-8
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is <7%. Metformin is the preferred first-line treatment, but most patients with type 2 diabetes eventually require multidrug therapy and/or insulin to achieve glycemic control.
Issue 1571 · May 6, 2019
Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)

View the Expanded Table: Some Available Insulins

Med Lett Drugs Ther. 2019 May 6; 61(1571):e73-7
View the Expanded Table: Some Available Insulins
Issue 1537 · January 1, 2018
Fiasp - Another Insulin Aspart Formulation for Diabetes

The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional…

Med Lett Drugs Ther. 2018 Jan 1; 60(1537):6-7
The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional insulin aspart (Novolog) .
Issue 1512 · January 16, 2017
Drugs for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to…

Med Lett Drugs Ther. 2017 Jan 16; 59(1512):9-18
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to this target has been shown to prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular outcomes is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease, a history of severe hypoglycemia, diabetes-related complications or comorbidities, or a long duration of disease.
Issue 1463 · March 2, 2015
An Inhaled Insulin (Afrezza)

The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin ( Afrezza – Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1…

Med Lett Drugs Ther. 2015 Mar 2; 57(1463):34-5
The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin ( Afrezza – Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1 diabetes, the drug must be used in combination with long-acting insulin. Another inhaled, rapid-acting insulin (Exubera) was approved in 2006 for the same indication, but was withdrawn from the market the following year.